# Primary Radiotherapy In MEtastatic Lung Cancer

> **NCT07135882** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 420 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung (NSCLC)

## Interventions

- **COMBINATION_PRODUCT:** Radiotherapy followed by chemotherapy
- **DRUG:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT07135882
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-01-01
- **Final completion:** 2033-01-01
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07135882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07135882, "Primary Radiotherapy In MEtastatic Lung Cancer". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT07135882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*